Medical Weight Loss

ILU Collective offers physician-supervised medical weight loss programs using GLP-1 receptor agonist medications, including FDA-approved semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro / Zepbound). Each program includes a medical consultation, bloodwork, personalized dosing, and monthly check-ins. Compounded versions of GLP-1 medications are not FDA-approved and are prepared under physician supervision. Individual results vary.

Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes management that has also been approved for chronic weight management under the brand name Wegovy. It works by mimicking a natural hormone that may help regulate appetite and food intake. At ILU Collective, semaglutide is prescribed and monitored under physician supervision with personalized dosing. Compounded versions are not FDA-approved and are prepared under physician supervision. Individual results vary.

At ILU Collective, all GLP-1 weight loss programs are conducted under the direct medical supervision of Dr. Lourdes Bosch, Medical Director, in compliance with Florida Statute 458.3265. This includes a thorough medical evaluation, baseline bloodwork, careful dose titration, and ongoing monitoring. As with any medication, potential side effects should be discussed with your provider during your consultation. Individual results vary.

Medical weight loss at ILU Collective is a physician-supervised program that may include FDA-approved medications, lab monitoring, and personalized clinical oversight - rather than relying solely on calorie restriction or exercise. GLP-1 medications may help regulate appetite signals, which can support adherence to a healthier lifestyle. Your provider designs a protocol tailored to your health profile and goals. Individual results vary.

Weight loss outcomes with GLP-1 therapy depend on many individual factors, including starting weight, metabolism, adherence to the program, and lifestyle habits. Clinical studies on FDA-approved semaglutide have shown meaningful weight reduction in participants over time. Your provider at ILU Collective will set realistic expectations during your consultation based on your medical history and goals. Individual results vary.

No, most clients at ILU Collective visit monthly for weight loss check-ins, which include progress assessment, dose adjustment, and ongoing lab monitoring as needed. GLP-1 medications are typically self-administered at home via a weekly injection. Your provider will establish a visit schedule that fits your protocol and progress. Individual results vary.

A weight loss consultation at ILU Collective includes a comprehensive medical history review, baseline bloodwork panel, body composition assessment, and a one-on-one discussion with your provider about your goals and candidacy for GLP-1 therapy. Based on your results, a personalized protocol is designed under physician supervision. Contact us at (786) 539-3085 to schedule your consultation.

ILU Collective is an in-person medical practice located at 135 Madeira Ave in Coral Gables, FL. All weight loss consultations, evaluations, and prescriptions are managed through our clinic under physician supervision. We do not operate as an online pharmacy or ship medications directly. Clients receive their prescriptions through licensed pharmacies as part of their supervised treatment plan.